

Vera H M Deneer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6493838/publications.pdf>

Version: 2024-02-01

18
papers

733
citations

759233

12
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

1071
citing authors

#	ARTICLE	IF	CITATIONS
1	Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. <i>Lancet</i> , The, 2020, 395, 1374-1381.	13.7	205
2	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>European Journal of Human Genetics</i> , 2020, 28, 508-517.	2.8	127
3	Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPx Guidelines. <i>Frontiers in Pharmacology</i> , 2020, 11, 595219.	3.5	103
4	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 795-801.	4.7	71
5	Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG). <i>Circulation</i> , 2020, 142, 1799-1807.	1.6	37
6	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. <i>European Journal of Human Genetics</i> , 2022, 30, 1114-1120.	2.8	37
7	Use of Pharmacogenetic Drugs by the Dutch Population. <i>Frontiers in Genetics</i> , 2019, 10, 567.	2.3	32
8	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). <i>European Journal of Human Genetics</i> , 2022, 30, 1105-1113.	2.8	22
9	Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Thoracic Cancer</i> , 2020, 11, 1790-1800.	1.9	20
10	Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. <i>Pharmacogenomics</i> , 2018, 19, 621-628.	1.3	19
11	The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1554-1564.	7.3	18
12	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 195-206.	2.2	13
13	Pharmacogenetics of antitumor necrosis factor therapy in severe sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 267-276.	2.6	6
14	Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study. <i>Thoracic Cancer</i> , 2020, 11, 3634-3640.	1.9	5
15	Ticagrelor Versus Clopidogrel in Older Patients with NSTEMI-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3249.	2.4	5
16	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	2.5	5
17	Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 9, 76-84.	3.0	3
18	Effect of CYP3A4*22 and PPAR-1 Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. <i>Genes</i> , 2020, 11, 1068.	2.4	2